Olivier Bogillot
President chez PROVENTION BIO, INC.
Profil
Olivier Bogillot currently works at Sanofi-Aventis France SA, as Chairman & Chief Executive Officer, Sanofi Pasteur Merieux SAS, as Chairman from 2020, and Provention Bio, Inc., as President & Director from 2023.
Postes actifs de Olivier Bogillot
| Sociétés | Poste | Début |
|---|---|---|
| PROVENTION BIO, INC. | President | 27/04/2023 |
Sanofi-Aventis France SA
 Sanofi-Aventis France SA Medical DistributorsDistribution Services Sanofi-Aventis France engages in wholesale of pharmaceutical products. The company is headquartered in Gentilly, France. | Directeur Général | - |
Sanofi Pasteur Merieux SAS
 Sanofi Pasteur Merieux SAS Financial ConglomeratesFinance Part of Sanofi, Sanofi Pasteur Merieux SAS is a French healthcare company that offers a wide range of medicines, vaccines, and healthcare products in various therapeutic areas. The company is based in Paris, France. Sanofi France is committed to promoting diversity and inclusion by supporting young people in employment, integrating the LGBT+ community, people with disabilities, and promoting gender equality. | Président | 01/03/2020 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Sanofi Pasteur Merieux SAS
Sanofi Pasteur Merieux SAS Financial ConglomeratesFinance Part of Sanofi, Sanofi Pasteur Merieux SAS is a French healthcare company that offers a wide range of medicines, vaccines, and healthcare products in various therapeutic areas. The company is based in Paris, France. Sanofi France is committed to promoting diversity and inclusion by supporting young people in employment, integrating the LGBT+ community, people with disabilities, and promoting gender equality. | Finance |
Sanofi-Aventis France SA
Sanofi-Aventis France SA Medical DistributorsDistribution Services Sanofi-Aventis France engages in wholesale of pharmaceutical products. The company is headquartered in Gentilly, France. | Distribution Services |
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
